Treatment of Refractory Cancer‐associated Hypercalcemia with Aminohydroxypropylidene Diphosphonate

JAMES G. HEAF, M. HANSEN

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    ABSTRACT The case history is presented of a 45‐year‐old woman who was receiving chemotherapy for a pulmonary adenocarcinoma and who developed severe symptomatic hypercalcemia. Despite intensive treatment with fluids. loop diuretics, prednisone, calcitonin and repeated doses of mithramycin, she remained hypercalcemic. She was then treated with aminohydroxypropylidene diphosphonate (APD) with consequent rapid normalization of the serum calcium and disappearance of symptoms. We conclude that APD is a valuable supplement to the treatment of malignant hypercalcemia in that it may be effective when traditional therapies have failed. 1988 Association for the Publication of the Journal of Internal Medicine

    OriginalsprogEngelsk
    Sider (fra-til)287-288
    Antal sider2
    TidsskriftActa Medica Scandinavica
    Vol/bind224
    Udgave nummer3
    DOI
    StatusUdgivet - 1 jan. 1988

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Treatment of Refractory Cancer‐associated Hypercalcemia with Aminohydroxypropylidene Diphosphonate' indeholder.

    Citationsformater